Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression
Timotius Ivan Hariyanto, Andree Kurniawan
Topics & Concepts
MedicineMeta-analysisDipeptidyl peptidase-4Internal medicineLinagliptinCoronavirus disease 2019 (COVID-19)Diabetes mellitusSubgroup analysisDipeptidyl peptidase-4 inhibitorRandom effects modelType 2 diabetesMeta-regressionType 2 Diabetes MellitusDiseaseEndocrinologyInfectious disease (medical specialty)Diabetes Treatment and ManagementCOVID-19 Clinical Research StudiesPeptidase Inhibition and Analysis